Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01550887
Other study ID # ANNA2011
Secondary ID
Status Completed
Phase N/A
First received December 12, 2011
Last updated August 10, 2015
Start date April 2012
Est. completion date May 2015

Study information

Verified date August 2015
Source Federal University of São Paulo
Contact n/a
Is FDA regulated No
Health authority Brazil: Ethics Committee
Study type Interventional

Clinical Trial Summary

This study main objective is investigating impulsivity on cocaine or crack addicts. The investigators main hypothesis is that different measures (such as scales or behavioral tasks, for example) of impulsivity may produce distinct outcomes, and they might also differ among cocaine (sniffed) and crack users. Thus, it would be of great value to compare such measures once these data are often interpreted as the same phenomenon.


Description:

Drug dependence is characterized by a sum of cognitive, behavioral and physiological symptoms. Among these symptoms are the lack of control over ones own behavior and substance use even in face of significant issues related to it. Impulsivity (expressed as impulsive choice or fail on behavioral inhibition) is important in crucial phases of drug dependence development. Both behavioral and neurobiological studies have confirmed the association between impulsivity and addictive behaviors. Thus a high impulsivity level might have influence on patients' treatment. Even though, several questions on this matter remain unclear for humans, such as the differences on impulsivity between users of different forms of cocaine (either sniffed or smoked). This kind of difference could establish distinct ways of treatment and then enable developing better treatments for drug users. For this study it will be recruited 60 non-treated dependent patients, among them 30 cocaine users and 30 crack users. These individuals will be selected based on DSM-IV dependence criteria. The instruments used will be scales to measure compulsion and consumption of cocaine/crack, a pharmacological screening for psychotropic drugs and a cognitive evaluation. As impulsivity measures are Barratt Impulsivity Scale (BIS 11), a reward discounting questionnaire and a computer-based behavioral test on "ProgRef v3" software. For data analysis the impulsivity measures will be compared with the behavioral and cognitive instruments through the Pearson's correlation matrix. An ANOVA will be also performed to verify any differences between cocaine and crack dependents on the impulsivity and compulsion tests. When it is appropriate subsequent Newman-Keuls post-hoc test will be performed. Significance level adopted is 0.05.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 2015
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Male

- 18-50 years old

- Cocaine/ Crack dependence criteria according to DSM-IV

- Have at least high school education level

Exclusion Criteria:

- Present dependence criteria for other drugs, except for Nicotine/tabacco

- Have any other psychiatric conditions

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No intervention will be performed on this study

Locations

Country Name City State
Brazil UDED São Paulo SP

Sponsors (3)

Lead Sponsor Collaborator
Federal University of São Paulo Associação Fundo de Incentivo à Pesquisa, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impulsive trait, as measured by different tests. To mesure "impulsive trait", will be used the Barratt Impulsivity Scale (BIS 11), the Reward Discounting Questionnaire and a computer-based Behavioral Test on "ProgRef v3" software. An expected average of 2 months No
See also
  Status Clinical Trial Phase
Completed NCT00887367 - EtOH Interaction Study Phase 1
Completed NCT01036061 - GSK618334 Repeat Dose Study Phase 1
Completed NCT01189799 - Motivational Therapy for Substance Users With Depression N/A
Completed NCT01381133 - Adolescent Outpatient and Continuing Care Study Phase 3
Recruiting NCT04430257 - Pre-exposure Prophylaxis (PrEP) for Health N/A
Completed NCT01128140 - Efficacy Trial of Warrior Check-Up Phase 2
Completed NCT03767907 - Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial N/A
Recruiting NCT05833399 - Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
Withdrawn NCT01515917 - Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI) N/A
Completed NCT00208143 - Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Phase 4
Withdrawn NCT03762798 - Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone N/A
Completed NCT03048552 - Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 N/A
Active, not recruiting NCT04768920 - Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD) N/A
Recruiting NCT05410561 - Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients N/A
Recruiting NCT05679284 - A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
Withdrawn NCT00908206 - Effects of GSK598809 on Brain Activation in Abstinent Alcoholics Phase 1
Recruiting NCT05348317 - Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders N/A
Recruiting NCT01741415 - Distress Tolerance Treatment for Substance Users Phase 2
Active, not recruiting NCT01621711 - Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2